Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed his view on how the cell therapy field should proceed with regard to innovation.

The professor of neurology at the University of Texas Health Science Center San Antonio discussed discussed challenges of therapeutic development for OPMD.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Verve noted that a patient treated at the 0.6 mg/kg dose showed the maximum decrease in LDL-C levels: 69%.

FT819 is currently being evaluated in a multicenter phase 1 clinical trial.

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

The professor of neurology at the University of Texas Health Science Center San Antonio discussed the genetic basis of oculopharyngeal muscular dystrophy, as well as the primary challenges in diagnosing and treating the condition.

Review top news and interview highlights from the week ending April 11, 2025.

In observance of World Parkinson's Day, held annually on April 11, we took a look back at the past year's news in cell and gene therapy for PD.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the need to bring more innovations from nonclinical research to patients.

The data come from patients treated across 2 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his views on toxicities and costs associated with CAR-T, and when and how the field should address them.

A recent patient death following treatment with the gene therapy raised concerns for the European Medicines Agency.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his view on how the cell therapy field should proceed with regard to innovation.

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

The designations apply to lupus, myositis, and scleroderma indications.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, also discussed other future plans for the company.

Alcon noted additional operational updates alongside the announcement.

Review top news and interview highlights from the week ending April 4, 2025.

At 12 weeks posttreatment, all 4 of the patients showed improvement in the form of a lower logMAR.

The move was made in relation to the previously-announced death of a US teenager who received the therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief executive officer of Eledon Pharmaceuticals also discussed other future plans for the company.